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Abbreviations
Crea serum creatinine
BUN blood urea nitrogen 
COX-2 prostaglandin-endoperoxide synthase 2 (cyclooxygenase-2)
C control
CV CV247
CDDP cis-diammine-dichloroplatinum; trade name: Cisplatin
ICP-OES inductively coupled plasma optical emission spectrometry
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Abstract 
CV247,  an  aqueous  mixture  of  copper  and  manganese  gluconates,  vitamin  C  and 
sodium salicylate, increased the anti-tumour effects of cisplatin in vitro. We hypothesized that 
the antioxidant and cyclooxygenase (COX-2) inhibitory components of CV247 can protect the 
kidneys from cisplatin nephrotoxicity in rats.
Cisplatin  (6.5 mg/kg,  ip.)  slightly elevated serum creatinine (Crea)  and blood urea 
nitrogen (BUN) 12 days  after  treatment.  Kidney histology demonstrated  extensive tubular 
epithelial damage, and COX-2 immunoreactivity increased 14 days after treatment. Cisplatin 
increased  renal  platinum  (Pt)  but  decreased  iron  (Fe),  copper  (Cu),  manganese  (Mn), 
molybdenum  (Mo)  and  zinc  (Zn)  concentrations,  and  increased  plasma  Fe  and  Cu 
concentrations. Cisplatin elevated plasma free radical concentration. Treatment with CV247 
alone for 14 days (twice 3 ml/kg/day p.o.) did not influence these parameters.
Chronic CV247 administration after cisplatin reduced renal histological damage and 
almost significantly decreased COX-2 immunoreactivity,  while failed to improve Crea and 
BUN.  Blood  free  radical  concentration  was  decreased,  i.e.  CV247  improved  redox 
homeostasis. CV247 restored plasma Fe and renal Fe, Mo and Zn, while decreased renal Pt 
and elevated Cu and Mn concentrations.
Besides  the  known synergistic  anti-tumour  effects  with  cisplatin,  CV247  partially 
protected the kidneys from cisplatin nephrotoxicity probably through its antioxidant effect.
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Introduction 
Cisplatin  is  a  highly  effective  chemotherapeutic  agent  used  for  the  treatment  of  various 
malignancies.1-5 High-dose cisplatin-based combination chemotherapy regimens are used as 
first-line  treatment  of  small-cell  and  non-small  cell  lung  cancers.6-8 However,  the  use  of 
cisplatin is limited by serious side effects. Despite the use of different hydration protocols 
allowing dose escalation to therapeutic levels, nephrotoxicity is the main dose-limiting side 
effect of cisplatin.10-14 About 20% of acute renal failure cases was due to cisplatin among 
hospitalised patients. High-dose cisplatin-induced nephrotoxicity (>25% decrease in eGFR) 
was  diagnosed  in  29  % of  patients,  following  a  single  dose  of  cisplatin,  and  temporary 
elevation of serum creatinine concentration above the upper normal limit  was observed in 
41% of 400 cisplatin-treated patients with different solid tumours.17 Comorbidities in lung 
cancer patients greatly increased the incidence of cisplatin-induced nephrotoxicity from 7.5% 
without co-morbidities to 20.9% with concurrent hypertension with or without ischemic heart 
disease,  and  to  30.8%  with  diabetes  mellitus  and  ischaemic  heart  disease18.  Due  to  the 
superior efficacy of cisplatin against a variety of human carcinomas, intensive efforts have 
been undertaken to weaken the side effects especially the nephrotoxic effect of cisplatin.
During treatment,  cisplatin  accumulates  in  the kidney and thus,  by far the highest 
cisplatin concentration is measured in the kidney after treatment.19 Copper transporter 1 (Ctr1) 
and the organic cation transporter 2 (OCT2) are critically involved in cisplatin uptake into 
renal  tubular epithelial  cells  consequently determining nephrotoxicity20-23.  Oxidative stress, 
induction of an inflammatory response and direct DNA damage are also implicated in the 
mechanisms of cisplatin-induced nephrotoxicity. The importance of oxidative stress has been 
highlighted by numerous studies demonstrating, that antioxidant agents ameliorate cisplatin 
nephrotoxicity in experimental animals.24-26 The organic thiophosphate amifostine is an FDA 
approved protective agent against cisplatin nephrotoxicity27 although its efficacy could not be 
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unequivocally demonstrated in animal experiments. Alkaline phosphatase converts amifostine 
to a free thiol compound, which is citoprotective by binding free radicals.30 Acute or chronic 
treatment  with  vitamin  C  produced  encouraging  results  in  rat  experiments.31-34 Co-
administration of Vitamin E and selenium were also beneficial35.  Acetylsalicylic  acid and 
sodium salicylate were also protective.36-38
CV247  is  composed  of  manganese  and  copper  gluconates,  sodium  salicylate  and 
ascorbic acid (exact composition is given in the methods section), which are known to have 
antioxidant (ascorbic acid, manganese and copper), and TNFα inhibitor (sodium salicylate) 
effects. CV247 was shown to decrease the viability of six cancer cell lines in culture and to 
augment  the  cytotoxic  effect  of  cisplatin  against  human  breast  and  especially  colon 
carcinoma.. As some constituents of CV247 protected against kidney injury as shown above, 
it may also alleviate the cisplatin-induced nephrotoxicity by synergistically acting at several 
target sites. Therefore, the aim of this study was to investigate the net effects of CV247 on 
renal function, antioxidant status and kidney histology after cisplatin treatment.
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Materials and methods
Animals
The  study was  conducted  on  40 male,  8-week old  Wistar  rats  weighing  175-190 g.  The 
animals  were randomly divided into  4 groups (n=10/group).  They were kept  individually 
under standard conventional conditions according to European Council Directive 123. The 
study conformed to the Declaration of Helsinki guidelines and was approved by the local 
Animal Ethic Committee.
Test materials
Cisplatin (10 mg in 20 ml) was obtained from TEVA, Israel.  The composition of CV247 
(Pharmaserve Ltd, Manchester UK) was the following: 40 mg ascorbic acid, 2 mg manganese 
gluconate  (USP),  2  mg copper  gluconate,  35  mg sodium salicylate  per  millilitre  solution 
(www.ivymedical.com).  Methyl  cellulose mucilage  (Dow  Chemicals)  was  prepared  in 
distilled water (1 %). 
Protocol of the study
The control group (C) received 1% methyl cellulose at 10 ml/kg body weight, p.o. by gastric 
gavage twice daily  for  14 days.  Another  group of  rats  received  CV247 at  3  ml/kg  body 
weight, p.o. twice daily for 14 days (CV). The dose given was 2x120 mg/kg/day vitamin C, 
2x105 mg/kg/day sodium salicylate,  2x6 mg/kg/day copper  gluconate  and 2x6 mg/kg/day 
manganese  gluconate.  Two  groups  were  intraperitoneally  injected  with  a  single  dose  of 
cisplatin (CDDP) at 6.5 mg/kg body weight.41 CDDP was suspended in 10 ml/kg 1% methyl 
cellulose. One of the groups injected with CDDP was subsequently treated with vehicle (C) or 
CV at 3 ml/kg body weight, p.o. twice daily for 14 days (CDDP+CV). All rats were weighed 
and food and water consumptions were also measured daily. On day 12 1.5 ml blood samples 
were taken from all rats by retro orbital puncture under isoflurane anaesthesia after a 20-hour 
food deprivation. The blood was anticoagulated with citrate and centrifuged twice at 2500 
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rpm for 10 min at +4 C to obtain plasma. Plasma creatinine (Crea) and blood urea nitrogen 
(BUN) were determined from the plasma by colorimetric tests using commercially available 
kits. Rats were terminally anaesthetised with pentobarbitone on day 14. Blood was collected 
by aortic puncture and the kidneys were removed and weighed.
Induced chemiluminescence in the plasma 
A  small  volume  of  plasma  samples  (50-100  μl)  were  assayed  with  a  H2O2/.OH–
microperoxidase-luminol  system for  30 sec  as  described previously.42 Chemiluminescence 
was detected in a Berthold Lumat 9501 luminometer (Berthold GmbH, Germany).
Metal contents in the plasma and kidney
After digestion of the samples in nitric acid (5 ml 65%) and hydrogen peroxide (2 ml 30%), 
an inductively coupled plasma optical emission spectrometric (ICP-OES) method was used 
for measuring metal content43 in a Spectro Genesis ICP equipment (Kleve, Germany). For the 
standardization  of  equipment  and  measurements  of  elements  Spectro  multielement  and 
Spectrum 3D standards  were  used.  A computer  guided  TraceLab  50 type  polarographic-
voltammetric analyser was used for the voltammetric determination of selenium at -550 mV.44
Histology and immunohistochemistry
The kidneys were fixed in 8% buffered formalin (pH 7.4) and paraffin sections were prepared 
and  stained  with  haematoxylin–eosin.  Renal  histological  changes  were  blindly  evaluated 
using a 5-grade severity scale (0 = no change; 1 = minimal changes; 2 = mild changes; 3 = 
moderate  changes;  4  =  severe  changes).  The  cyclooxygenase-2  (COX-2) 
immunohistochemistry  was  done  using  a  mouse  monoclonal  COX-2  primary  antibody 
(Novocastra,  UK) at  1:100 dilution.  The secondary antibody was a peroxidase-conjugated 
mouse/rabbit  polymer  (Dako  Real™ Envision™ /HRP,  Rabbit/Mouse).  Diaminobenzidine 
was used for visualisation.
Statistical analysis
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Means±SD are given throughout.  The statistical  comparisons were performed by two-way 
repeated  measures  ANOVA with Bonferroni post hoc test  or Mann-Whitney U test  using 
GraphPad Prism 5 for Windows, or by two-way ANOVA using the SPSS 17 for Windows, 
when appropriate. The level of significance was set at p<0.05.
8/29
Results
Bodyweight
Body weight of rats steadily increased in group C from 171±8 g to 234±15 g over the 14 days 
of the study with a drop on day 11 after the overnight food deprivation (Fig. 1). In comparison 
to the baseline value, CDDP caused a 5.5 % peak body weight loss (p<0.001) from 167±6 g to 
158±9 g on day 3 after treatment. Thereafter, body weight gain returned to a rate similar to 
that seen in group C. CV treatment did not influence body weight in comparison to groups C 
and CDDP, respectively.  Consequently,  on the last  day of the study,  body weight  of rats 
treated with CDDP and CDDP+CV was 12-15 % lower (p<0.001) than body weight of rats in 
groups C and CV. 
Food and water consumptions
CV consistently  increased  water  consumption  in  comparison to  that  in  group C (Fig.  1), 
which was statistically significant on days 8, 9 and 11 (p<0.05, all). Cisplatin caused a short, 
non-significant decrease in water consumption on day 2 after its administration. Thereafter, 
from day 4 rats in the CDDP and CDDP+CV groups drank significantly more water than rats 
in  group  C.  Co-administration  of  CV  to  cisplatin  did  not  alter  water  consumption  in 
comparison  to  the  group treated  with  cisplatin  only.  Neither  CDDP nor  CV alone  or  in 
combination altered food consumption (data not shown).
Clinical chemistry
Crea and BUN values were within physiological limits in groups C and CV (Crea: 17.0-22.5 
µmol/l; BUN: 6.63- 10.48 mmol/l). CDDP increased both Crea and BUN concentrations at 
day 12 after its administration, while CV did not alter these effects of CDDP on renal function 
(Fig. 2).
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Plasma reactive oxidant levels increased 14 days after CDDP administration, as measured by 
chemiluminescence. CV did not alter chemiluminescence in comparison to group C while CV 
attenuated the CDDP-induced elevation in plasma reactive oxidant levels (Fig. 3).
Metal concentrations in the plasma and kidneys
Kidney Cu,  Fe,  Mn,  Mo and  Zn  concentrations  were  lower  in  the  kidney  14  days  after 
treatment with CDDP, while Co and Se concentrations did not change (p<0.05). Treatment 
with CV increased Mo concentrations in the kidney while it did not change other element 
concentrations  (Table 1).  Co-administration  of  CV with CDDP restored  renal  Fe and Zn 
concentrations  to  control  levels,  and  also  increased  renal  Cu  and  Mn  concentrations 
significantly, although Cu and Mn remained below the control levels. The effect of CDDP on 
renal Mo concentration was restored by CV. Surprisingly, kidney Pt concentration was 3 µg/g 
in the group treated with CDDP. CV strikingly reduced kidney Pt concentration by 30 % 
(p<0.05).
Plasma concentrations of Pt and Se were undetectable in untreated control animals. CDDP 
increased plasma Co and Fe concentrations (Table 2). Coadministration of CV with CDDP 
restored plasma Fe concentrations while CV did not alter the effect of CDDP on plasma Co 
concentrations.
Kidney histology and immunohistochemistry
No histological changes were seen in the kidneys in groups C and CV. Varying degrees of 
pathological  changes  were found in the kidneys  of CDDP and CDDP+CV groups.  Renal 
tubular epithelial cell atrophy presented as cystic dilatations of the tubular lumina, in which 
accumulation of desquamated tubular epithelial cells were present as hialynacous material. 
Many tubular  epithelial  cells  appeared  apoptotic  or  necrotic.  In  addition,  in  the  damaged 
tubular epithelium atypical, regenerating cells were visible. Tubulointerstitial inflammation 
presented as lymphocytic and macrophage infiltration in the interstitial space, accompanied 
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by interstitial  fibrosis  appearing  as  multiple  focal  presence  of  fibroblasts  (Fig.  4).  Blind 
assessment demonstrated a reduction in the mean score severity of histological kidney injury 
from  3.67±0.50  in  group  CDDP  to  2.67±0.71  in  group  CDDP+CV  (p<0.01). 
Immunohistochemistry revealed a moderate degree of focal COX-2 activity in the cytoplasm 
of the tubular epithelium, in the interstitial  space and in the walls of major blood vessels 
(score, control: 1.20±0.42 and CV: 1.0±0.0). Blind assessment of COX-2 activity revealed 
that  COX-2  immunoreactivity  markedly  increased  in  the  groups  treated  with  CDDP and 
CDDP+CV. Treatment with CV did not alter COX-2 immunoreactivity in comparison to that 
in group C but it almost significantly (3.00±0.71 vs. 2.44±0.53, p=0.097, Mann Whitney test) 
decreased the changes caused by CDDP (Fig. 5).
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Discussion
In the present study we demonstrated, that CV247, a potent enhancer of the anti-neoplastic 
effects of cisplatin, effectively protected the kidney from cisplatin toxicity as demonstrated by 
renal histology and restoration of redox and trace metal homestasis. However, slight renal 
retention of Crea and BUN 14 days after CDDP injection was not prevented by CV247. 
In group CDDP, histological damage was clearly present at day 14 after cisplatin injection, 
and immunohistochemistry revealed marked Cox-2 activation in the kidney,  as well as an 
increase  in  plasma  reactive  oxidant  levels,  detected  by  chemiluminescence.  Cisplatin 
decreased  copper,  manganese  and  zinc  concentrations  in  the  kidney,  which  minerals  are 
essential  cofactors  of  several  enzymes.  Chronic  treatment  of  rats  with  CV247  offered 
protection  against  cisplatin-induced  nephrotoxicity  demonstrated  by  attenuation  of 
histological injury,  restored plasma reactive oxidant levels and kidney copper content, and 
improved  kidney  manganese,  selenium  and  zinc  contents  at  14  days  after  cisplatin 
administration.  However, slight plasma creatinine and BUN retention still  present 14 days 
after CDDP injection and renal inflammation, as revealed by cox-2 immunohistochemistry, 
were not influenced by CV247.
It  has  been reported that  CDDP accumulated  in  the  kidney45 and renal  Pt  content 
decreased very slowly after cisplatin administration.46 It was an important observation in our 
study that chronic treatment with CV247 significantly decreased kidney platinum content by 
day 14 in comparison to the cisplatin alone group. Since administration of CV247 did not 
precede that of cisplatin, it can be excluded that CV247 interfered with renal cisplatin uptake. 
Therefore it seems likely that long-term administration of CV247 accelerated elimination of 
Pt from the kidney. This observation suggests that kidneys of CV247-treated rats recovered 
faster from the cisplatin-induced nephrotoxicity. 
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Most  importantly,  blind  assessment  of  tissue  pathology  demonstrated  that  CV247 
reduced the severity of renal histological injury. This observation seems to be in harmony 
with attenuation or full reversal of the cisplatin-induced decreases in trace mineral content of 
the kidney. These changes are compatible with the assumption that concentration of all those 
enzymes increased in the kidney, which use these minerals as cofactors for achieving their full 
activity. All these changes seem to suggest that manganese and copper constituents of CV247 
contributed to improve the biochemical machinery of the kidney. Although, only manganese 
and copper were supplemented,  it is well-known that trace mineral metabolism is subject to 
mutual synergisms and antagonisms.47 Therefore, administration of one or few trace minerals 
may also consequently alter the concentrations of other minerals in the kidney. 
A component  of  CV247,  sodium salicylate  inhibits  the activity  of  cyclooxygenase 
(COX-1  and  COX-2)  isoenzymes48.  COX-2  inhibition  is  anti-inflammatory  and  can  be  a 
renoprotective strategy as a highly selective  COX-2 inhibitor  (SC-58236) reduced urinary 
excretions  of  TGF-β,  TNF-α,  albumin,  PGE2,  6-ketoPGF1α  and  TxB2 in  streptozotocin-
diabetic rats.49 Our immunohistochemistry findings demonstrated that the cisplatin-induced 
elevation in COX-2 expression was almost significantly decreased by chronic treatment with 
CV247. In addition COX-2 enzyme activity may have been reduced by CV247 as sodium 
salicylate inhibits COX-2.48
The protective effect of sodium salicylate could be attributed to suppression of TNFα 
production as well.37 Treatment with acetyl salicylic acid or sodium salicylate for 4-5 days 
decreased plasma BUN and creatinine at a daily dose similar to that given by us38, restored the 
renal concentration of superoxide dismutase, and decreased oxidative stress as shown by renal 
malondialdehyde concentration in cisplatin nephrotoxicity.36 Such effects of sodium salicylate 
may help explain why CV247 accelerated histological recovery of the kidney from cisplatin 
nephrotoxicity in our study. 
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Even a 10 min pretreatment with various doses of vitamin C restored cisplatin-induced 
increases  in  plasma creatinine,  dose-dependently increased renal  glutathione  concentration 
and attenuated renal lipid peroxidation as assessed by malondialdehyde levels at one week 
after  cisplatin  injection.34 One hour  pretreatment  with a  medium dose  of  vitamin  C (100 
mg/kg/day) restored the changes in urinary 8-hydroxy-2’-deoxyguanosine caused by cisplatin 
suggesting that vitamin C prevented oxidative DNA damage.33 A single high vitamin C dose 
given six hours prior  to  cisplatin  also prevented  the decreases  in  the renal  cortical  brush 
border membrane enzyme (alkaline phosphatase,  leucine aminopeptidase,  gamma-glutamyl 
transferase and maltase) activities and transport of inorganic phosphate 4 days after cisplatin 
administration.32 However, the dose of 250 mg/kg was most effective in attenuating cisplatin-
induced  increases  in  plasma creatinine  and BUN concentrations  but  lower and especially 
higher vitamin C doses were less effective.32 In a light and electron microscopic study chronic 
daily  treatment  with vitamin C at  low dose (8 mg/kg)  decreased  renal  histological  injury 
caused by three repeated cisplatin administrations at 21 day intervals.31 These observations 
were similar to those seen in our study. Collectively we can conclude that pretreatment with 
vitamin  C  at  medium-high  doses  of  100-250  mg/kg  can  attenuate  cisplatin-induced 
nephrotoxicity. 
Cisplatin  elevated  iron concentration  in the plasma which  may induce free radical 
reactions.50 Treatment  with  CV247 restored  the  cisplatin-induced  increase  in  plasma  iron 
concentration. Otherwise plasma metal element content hardly differed from the control in the 
groups  treated  either  with  CV247  or  cisplatin+CV247.  The  restoration  of  plasma  iron 
concentration  in  the  group  treated  with  cisplatin+CV247  was  very  favourable  and  may 
explain the significant decrease of chemiluminescence intensity in the plasma. 
There is always some concern whether the efficacy of a drug is impaired or not when 
its side effects are aimed to be reduced by administration of an adjuvant. CV247 has been 
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shown to have a cytotoxic effect at the G2 phase in 4 malignant human cells lines (breast, 
prostate, colon and lung), and CV247 produced a synergistic effect with cisplatin in 3 breast 
and 3 colon carcinomas by increasing the cytotoxic efficacy of cisplatin up to four-fold in cell  
cultures.  These  observations  suggest  that  besides  offering  some  protection  from 
nephrotoxicity, CV247 may allow reducing the dose of cisplatin without altering its efficacy.
Cisplatin  also  blocks  the  normal  accumulation  of  Cu and Zn in  the  kidney.51 CV 
treatment was able to inhibit the depletion of Cu and Mn, but not of Zn. 
In conclusion, the current study demonstrated that chronic CV247 administration after 
treatment with cisplatin offered some protection against nephrotoxicity at two weeks in rats. 
Since previous studies have shown that CV247 had direct toxic effects on malignant cells and 
also synergically increased the anticancer effect of cisplatin in cancer cell lines CV247 may 
enable dose reduction of cisplatin  in cancer  patients.  A lower cisplatin  dose and a partial 
protection  against  nephrotoxicity  may  considerably  reduce  the  side  effect  of  cisplatin  in 
patients  treated  with  CV247.  However,  further  pharmacological  studies  are  needed  to 
demonstrate  that  CV247 also increases  the anticancer  effect  of  cisplatin  in  whole animal 
cancer models.
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Figure legends
Figure 1. 
The effects of acute cisplatin and chronic CV247 administration on the body weight and daily 
water consumption in rats (n=10/group). Left panel: body weight. The asterisk (*) shows that 
from day 3 body weight was significantly decreased in the groups treated with cisplatin and 
cisplatin + CV247 in comparison to the groups treated with vehicle and CV247. Right panel: 
water  consumption.  The  asterisk  (*)  shows  that  from  day  5  water  consumption  was 
significantly  increased  in  the  groups  treated  with  cisplatin  and  cisplatin  +  CV247  in 
comparison to the group treated with vehicle. The open circles show that on days 8, 9 and 11 
water  consumption  was  significantly  increased  in  the  group  treated  with  CV247  in 
comparison to the group treated with vehicle. The statistical analysis was performed by two-
way repeated measures ANOVA followed by Bonferroni post hoc test.
Figure 2.
The effects of acute cisplatin and chronic CV247 administration on plasma creatinine and 
blood urea  nitrogen  concentration  on  day 12 in  rats  (n=10/group).  CDDP increased  both 
plasma creatinine and blood urea nitrogen (BUN) concentrations on day 12 of the experiment. 
CV247 did not alter  plasma creatinine and BUN concentrations compared to those of the 
groups treated either with vehicle or with CDDP. Group effects of CDDP and CV247 and 
their interaction were obtained from two-way ANOVA. 
Figure 3.
The effects  of  acute  cisplatin  and chronic  CV247 administration  on the  free radical-  and 
reactive  oxygen  species  (ROS)-scavenging  ability  of  the  serum  of  rats  measured  by 
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chemiluminescence  (RLU%) on  day  14 after  cisplatin  administration.  Cisplatin  increased 
while CV247 decreased plasma chemiluminescence. Group effects of CDDP and CV247 and 
their interaction were obtained from two-way ANOVA.
Figure 4.
The  effects  of  acute  cisplatin  and  chronic  CV247  administration  on  kidney  histology 
(haematoxylin–eosin staining). The structure of the kidney was normal in the C (A) and CV 
groups (C). Severe degree of tubulointerstitial abnormality was present in rats treated with 
CDDP  (B),  and  similar  but  significantly  less  severe  (CDDP:  3.67±0.50  vs.  CDDP+CV: 
2.67±0.71; p<0.01) alterations were detected in the group treated with CDDP+CV (D). See 
higher  magnification  of  sections  from the group CDDP (E) and CDDP+CV (F).  Blinded 
scores of histological abnormalities were statistically compared by two-way ANOVA.
Figure 5.
The  effects  of  acute  cisplatin  and  chronic  CV247  administration  on  COX-2 
immunohistochemistry  in  the  renal  cortex.  Mild  activity  in  the  interstitium  and  tubular 
epithelium was present in rats treated with vehicle (A) and CV (C). CDDP increased COX-2 
activity  in  the  damaged  areas  of  the  kidney  (B),  which  effect  was  almost  significantly 
decreased (3.00±0.71 vs. 2.44±0.53, p=0.097, Mann Whitney test) by CV (D). See higher 
magnification of sections from the group CDDP (E) and CDDP+CV (F). Blinded scores of 
COX-2 immunoreactivity were statistically compared by two-way ANOVA.
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Table 1. Element concentrations of rat kidneys (μg/g) measured by ICP-OES
Element concentration ANOVA
C CDDP CV CDDP+CV CDDP CV CDDP*CV
μg/g μg/g μg/g μg/g p< p< p<
Cobalt (Co) 0.25±0.03 0.21±0.05 0.23±0.03 0.21±0.05 0.053 0.384 0.382
Copper (Cu) 5.09±0.50 2.85±0.61 5.07±0.80 3.86±0.54 0.001 0.024 0.016
Iron (Fe) 42.5±4.1 33.4±3.4 38.2±2.8 38.7±4.4 0.001 0.743 0.001
Manganese (Mn) 0.81±0.12 0.51±0.10 0.79±0.08 0.60±0.07 0.001 0.01 0.032
Molybdenum 
(Mo) 0.23±0.02 0.19±0.03 0.26±0.02 0.23±0.04
0.001 0.001 0.662
Platinum (Pt) BLQ 3.05±0.58 BLQ 2.07±0.25 - 0.001 -
Selenium (Se) 0.19±0.16 0.13±0.06 0.21±0.09 0.29±0.15 0.895 0.202 0.331
Zinc (Zn) 16.1±1.38 13.2±1.51 15.1±0.82 15.0±0.70 0.001 0.340 0.001
BLQ: below limit of quantitation. Statistical analysis was performed 
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Table 2. Element content in rat plasma (μg/g) measured by ICP-OES
Element concentration ANOVA
C CDDP CV CDDP+CV CDDP CV CDDP*CV
μg/g μg/g μg/g μg/g p< p< p<
Copper 0.824±0.101 0.957±0.116 0.820±0.069 0.961±0.201 0.002 0.993 0.916
Iron 3.56±0.97 5.89±1.87 3.81±1.63 3.46±0.68 0.046 0.029 0.008
Manganese 0.026±0.012 0.041±0.025 0.024±0.012 0.029±0.016 0.082 0.208 0.378
Molybdenu
m 0.056±0.020 0.067±0.019 0.041±0.022 0.045±0.024
0.263 0.017 0.644
Zinc 1.37±0.27 1.48±0.18 1.33±0.12 1.27±0.17 0.738 0.076 0.233
Plasma cobalt and selenium concentrations were below limit of quantitation in most cases. 
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